Transgene: Composition of the Board of Directors and Statutory Auditors

information fournie par Boursorama •25/05/2016 à 18:30

Composition of the Board of Directors and Statutory Auditors



Strasbourg, France, May 25, 2016 – Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the new composition of its board of directors and the appointment of new statutory auditors following yesterday’s annual shareholders’ meeting (AGM).

The AGM appointed Mr Antoine Béret as an independent director, to replace Mr Arnaud Fayet who did not seek a renewal of his term.